Small molecule · developed by Evotec Neurosciences GmbH
EVT 302 is a drug studied in smoking cessation, given double-blind alongside open-label nicotine replacement.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00738595 | Phase 2 | Smoking Cessation | Completed | EVO |
| NCT00622752 | Phase 2 | Smoking Cessation | Completed | EVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Smoking Cessation
Updated Nov 15, 2026. Something wrong or missing? Report it on the EVO page.
See EVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EVO catalysts and pipeline →